The effectiveness of glucocorticoid treatment in post-COVID-19
pulmonary involvement

J 2024

The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement

MIZERA, Jan, Samuel GENZOR, Milan SOVA, Ladislav STANKE, Radim BURGET et. al.

Základní údaje

Originální název

The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement

Autoři

MIZERA, Jan (203 Česká republika), Samuel GENZOR (203 Česká republika), Milan SOVA (203 Česká republika, domácí), Ladislav STANKE (203 Česká republika), Radim BURGET (203 Česká republika), Petr JAKUBEC (203 Česká republika), Martin VYKOPAL (203 Česká republika), Pavol POBEHA (203 Česká republika) a Jana ZAPLETALOVA (203 Česká republika)

Vydání

PNEUMONIA, AUSTRALIA, LONDON, 2024, 2200-6133

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 8.500 v roce 2023

Kód RIV

RIV/00216224:14110/24:00138636

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1186/s41479-023-00123-7

UT WoS

001156289200001

Klíčová slova anglicky

Post-covid syndrome; Pulmonary fibrosis; Corticosteroids; Watchful waiting; Pulmonary function

Štítky

14110215, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 1. 2025 09:33, Mgr. Tereza Miškechová

Anotace

V originále

RationalePersistent respiratory symptoms following Coronavirus Disease 2019 (COVID-19) are associated with residual radiological changes in lung parenchyma, with a risk of development into lung fibrosis, and with impaired pulmonary function. Previous studies hinted at the possible efficacy of corticosteroids (CS) in facilitating the resolution of post-COVID residual changes in the lungs, but the available data is limited.AimTo evaluate the effects of CS treatment in post-COVID respiratory syndrome patients.Patients and methodsPost-COVID patients were recruited into a prospective single-center observational study and scheduled for an initial (V1) and follow-up visit (V2) at the Department of Respiratory Medicine and Tuberculosis, University Hospital Olomouc, comprising of pulmonary function testing, chest x-ray, and complex clinical examination. The decision to administer CS or maintain watchful waiting (WW) was in line with Czech national guidelines.ResultsThe study involved 2729 COVID-19 survivors (45.7% male; mean age: 54.6). From 2026 patients with complete V1 data, 131 patients were indicated for CS therapy. These patients showed significantly worse radiological and functional impairment at V1. Mean initial dose was 27.6 mg (SD +/- 10,64), and the mean duration of CS therapy was 13.3 weeks (SD +/- 10,06). Following therapy, significantly better improvement of static lung volumes and transfer factor for carbon monoxide (DLCO), and significantly better rates of good or complete radiological and subjective improvement were observed in the CS group compared to controls with available follow-up data (n = 894).ConclusionBetter improvement of pulmonary function, radiological findings and subjective symptoms were observed in patients CS compared to watchful waiting. Our findings suggest that glucocorticoid therapy could benefit selected patients with persistent dyspnea, significant radiological changes, and decreased DLCO.

Citovat

MIZERA, Jan, Samuel GENZOR, Milan SOVA, Ladislav STANKE, Radim BURGET, Petr JAKUBEC, Martin VYKOPAL, Pavol POBEHA a Jana ZAPLETALOVA. The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement. PNEUMONIA. AUSTRALIA: LONDON, 2024, roč. 16, č. 1, s. 1-10. ISSN 2200-6133. Dostupné z: https://dx.doi.org/10.1186/s41479-023-00123-7.

@article{2471456,
   author = {Mizera, Jan and Genzor, Samuel and Sova, Milan and Stanke, Ladislav and Burget, Radim and Jakubec, Petr and Vykopal, Martin and Pobeha, Pavol and Zapletalova, Jana},
   article_location = {AUSTRALIA},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s41479-023-00123-7},
   keywords = {Post-covid syndrome; Pulmonary fibrosis; Corticosteroids; Watchful waiting; Pulmonary function},
   language = {eng},
   issn = {2200-6133},
   journal = {PNEUMONIA},
   title = {The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement},
   url = {https://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00123-7},
   volume = {16},
   year = {2024}
}

TY  - JOUR
ID  - 2471456
AU  - Mizera, Jan - Genzor, Samuel - Sova, Milan - Stanke, Ladislav - Burget, Radim - Jakubec, Petr - Vykopal, Martin - Pobeha, Pavol - Zapletalova, Jana
PY  - 2024
TI  - The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement
JF  - PNEUMONIA
VL  - 16
IS  - 1
SP  - 1-10
EP  - 1-10
PB  - LONDON
SN  - 22006133
KW  - Post-covid syndrome
KW  - Pulmonary fibrosis
KW  - Corticosteroids
KW  - Watchful waiting
KW  - Pulmonary function
UR  - https://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00123-7
N2  - RationalePersistent respiratory symptoms following Coronavirus Disease 2019 (COVID-19) are associated with residual radiological changes in lung parenchyma, with a risk of development into lung fibrosis, and with impaired pulmonary function. Previous studies hinted at the possible efficacy of corticosteroids (CS) in facilitating the resolution of post-COVID residual changes in the lungs, but the available data is limited.AimTo evaluate the effects of CS treatment in post-COVID respiratory syndrome patients.Patients and methodsPost-COVID patients were recruited into a prospective single-center observational study and scheduled for an initial (V1) and follow-up visit (V2) at the Department of Respiratory Medicine and Tuberculosis, University Hospital Olomouc, comprising of pulmonary function testing, chest x-ray, and complex clinical examination. The decision to administer CS or maintain watchful waiting (WW) was in line with Czech national guidelines.ResultsThe study involved 2729 COVID-19 survivors (45.7% male; mean age: 54.6). From 2026 patients with complete V1 data, 131 patients were indicated for CS therapy. These patients showed significantly worse radiological and functional impairment at V1. Mean initial dose was 27.6 mg (SD +/- 10,64), and the mean duration of CS therapy was 13.3 weeks (SD +/- 10,06). Following therapy, significantly better improvement of static lung volumes and transfer factor for carbon monoxide (DLCO), and significantly better rates of good or complete radiological and subjective improvement were observed in the CS group compared to controls with available follow-up data (n = 894).ConclusionBetter improvement of pulmonary function, radiological findings and subjective symptoms were observed in patients CS compared to watchful waiting. Our findings suggest that glucocorticoid therapy could benefit selected patients with persistent dyspnea, significant radiological changes, and decreased DLCO.
ER  -

MIZERA, Jan, Samuel GENZOR, Milan SOVA, Ladislav STANKE, Radim BURGET, Petr JAKUBEC, Martin VYKOPAL, Pavol POBEHA a Jana ZAPLETALOVA. The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement. \textit{PNEUMONIA}. AUSTRALIA: LONDON, 2024, roč.~16, č.~1, s.~1-10. ISSN~2200-6133. Dostupné z: https://dx.doi.org/10.1186/s41479-023-00123-7.

Přehled o publikaci